Biotech startup specialising in the research and development of CD31 agonists to restore immune balance
Tridek-One has raised €16M across 1 funding round from 5 investors, most recently a round in Sep 2022. Based in Paris, France; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-09-15 | Other | €16M |
| AdBio partners,Advent Life Sciences,Bioqube Ventures,Bpifrance,Swiss VC Pureos Bioventures |
| View deal → |
